StockpollyBeta
Get App
Popularity #5,028
XLO · NASDAQ · Biotechnology

Xilio Therapeutics (XLO)

Develops masked immuno-oncology therapies designed to activate within tumors.

$8.94
vs last close−0.10 (−1.11%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0002223819141319
Cost of revenue0000000150000
Gross profit0002223−719141219
17181717171517721262622
Research & development1112101111981514182015
666667977778
Selling & marketing000000000000
General & administrative606667977778
Other expenses0010000−150000
Operating income−17−18−17−15−15−14−14−14−2−12−14−3
1001111−1−14225−3
Interest income000000000000
Interest expense000000000000
Other non-operating income0−1−100−1−1114−22−53
Income before tax−17−18−17−14−14−13−13−16−1610−10−6
Net income from continuing operations−17−18−17−14−14−13−13−16−1610−10−6
Net income−17−18−17−14−14−13−13−16−1610−10−6
EPS, basic−$8.54−$8.96−$8.68−$4.48−$3.08−$2.80−$2.52−$4.34−$1.54$0.96−$0.58−$0.33
EPS, diluted−$8.54−$8.96−$8.68−$4.48−$3.08−$2.80−$2.52−$4.34−$1.54$0.81−$0.58−$0.33
Weighted average shares, basic2———————108416319
Weighted average shares, diluted2———————108416319
EBITDA−17−17−16−14−14−13−13−15−1611−9−6
Depreciation & amortization000000000000
EBIT−17−18−17−15−15−13−13−16−1610−10−6